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Background: This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and
antitumor activity of ganetespib in patients with solid malignancies.
Methods: Patients were enrolled in cohorts of escalating ganetespib doses, given as 1 hour IV infusion, once
weekly for 3 weeks, followed by a 1-week rest until disease progression or unacceptable toxicity. Endpoints
included safety, pharmacokinetic and pharmacodynamic parameters and preliminary clinical activity.
Results: Fifty-three patients were treated at doses escalating from 7 to 259 mg/m2. The most common adverse
events were Grade 1 and 2 diarrhea, fatigue, nausea or vomiting. Dose-limiting toxicities (DLT) observed were: one
Grade 3 amylase elevation (150 mg/m2), one Grade 3 diarrhea and one Grade 3 and one Grade 4 asthenia
(259 mg/m2). The MTD was 216 mg/m2 and the recommended phase 2 dose was established at 200 mg/m2 given
IV at Days 1, 8, and 15 every 4 weeks. There was a linear relationship between dose and exposure. Plasma HSP70
protein levels remained elevated for over a week post treatment. Disease control rate (objective response and
stable disease at ≥ 16 weeks) was 24.4%.
Conclusions: Ganetespib is well tolerated as a weekly infusion for 3 of every 4 weeks cycle. The recommended
phase II dose is 200 mg/m2, and is associated with an acceptable tolerability profile.
Trial registration: NCT00687934
Keywords: Ganetespib, Hsp90 inhibitor, Pharmacokinetics, Phase I study, Solid tumorsBackground
Heat shock protein 90 (Hsp90) belongs to a class of mo-
lecular chaperone proteins that helps modulate cellular re-
sponses to environmental stress, and regulates the folding,
stability, and function of many so-called “client” proteins,
such as RAF, KIT, EGFR, HER2, PDGFRα and VEGFR2
[1]. These client proteins play critical roles in tumor
growth, evasion of apoptosis, angiogenesis, and tissue in-
vasion [2-4]. Inhibition of Hsp90 is believed to cause these
client proteins to adopt aberrant conformations, which are* Correspondence: jwgoldman@mednet.ucla.edu
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reproduction in any medium, provided the orthen targeted for ubiquitination and degradation by the
proteasome, thereby providing simultaneous targeting of
multiple oncogenic signaling pathways [5-7]. In addition
to client protein degradation, induction of heat shock pro-
tein 70 (HSP70) is another feature of Hsp90 inhibition.
HSP70 is also a molecular chaperone that is known to play
a key role in the Hsp90 chaperone complex machinery
[8,9]. In this regard, HSP70 up-regulation is a commonly
used biomarker for Hsp90 inhibition in clinical trials [10].
In most cases, pharmacodynamic analyses of Hsp90 inhib-
itors have focused on cytosolic HSP70 levels using circu-
lating peripheral blood mononuclear cells (PBMCs) as a
surrogate tissue for tumor-specific activity. However, be-
cause HSP70 has been documented to be secreted byal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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plasma levels of HSP70 have been proposed to represent a
potentially more robust and reproducible biomarker for
Hsp90 inhibition [11].
Ganetespib (STA-9090), 5-[2,4-dihydroxy-5-(1 methyl-
ethyl)phenyl]-2,4 dihydro-4-(1-methyl-1H indol-5 yl)-3H-
1,2,4 triazole-3-one, is a novel triazolone heterocyclic
Hsp90 inhibitor [12], structurally unrelated to geldana-
mycin-derived inhibitors such as 17-AAG, 17-DMAG and
IPI-504 (Figure 1A). Ganetespib exerts its action by binding
to the ATP pocket in the N-terminus of Hsp90, leading to
down-regulation of Hsp90 client protein levels. Preclinical
studies reveal potent Hsp90 inhibition and activity against a
range of models including lung, prostate, colon, breast,
melanoma and leukemia [13-15]. In non-small cell lung
cancer (NSCLC) models in particular, ganetespib effectively
destabilizes a number of oncogenic drivers, including the
KRAS effector CRAF and PDGFRα, that in turn inactivates
downstream MAPK and AKT signaling to induce apoptosis
[16]. In combination with taxanes, ganetespib is also highly
efficacious in NSCLC models that express the activated and
erlotinib resistant form of the epidermal growth factor re-
ceptor (EGFRL858R/T790M) [17].
This study was undertaken to determine the maximum
tolerated dose (MTD), and the recommended phase II
dose (RP2D) in solid tumors.
Methods
Study design
This open-label, dose-escalation study was conducted at 2
centers (Premiere Medical Center [currently UCLA, Santa
Monica, CA] and KHN Innovation Center, US Oncology,
Kettering, OH). The primary objectives were to charac-
terize the safety and tolerability of a once-weekly adminis-
tration, determine the recommended phase II dose
(RP2D) of ganetespib, pharmacokinetics (PK), pharmaco-
dynamics (PD), and preliminary clinical activity. The study
was approved by the Institutional Review Board at bothFigure 1 Chemical structures of Hsp90 inhibitors and ganetespib con
prototypical geldanamycin-derived Hsp90 inhibitor (right); (B) Representativ
Red circles represent Day 1, blue squares represent Day 15.centers and was carried out in accordance with Good
Clinical Practice.
Eligibility criteria
Eligible patients had pathologically confirmed advanced
solid tumors, whose disease was refractory to prior therap-
ies or for whom no further standard therapy existed. Pa-
tients were required to be ≥ 18 years of age; with Eastern
Cooperative Oncology Group (ECOG) performance status
(PS) ≤ 2; adequate hematologic, renal and hepatic func-
tions; and left ventricular ejection fraction (LVEF) greater
than 45%. Measurable disease was not required for entry.
Primary brain tumors were excluded, but patients with
stable brain metastases were eligible. All patients gave
written informed consent according to institutional and
federal guidelines.
Study assessments
Patients’ demographics and medical history were recorded
at baseline. Physical examination and PS were assessed at
baseline and on Day 1 of each cycle. Adverse events (AEs),
vital signs, hematology and chemistry values, and creatin-
ine clearance were assessed at baseline and weekly during
treatment. Toxicity was graded using National Cancer
Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE), version 3.0. An electrocardiogram
(ECG) was performed at baseline, before and after treat-
ment on Days 1 and 15 of Cycles 1 and 2, and on Day 15
of even-numbered cycles thereafter. CT scans were done
at baseline and every 8 weeks thereafter. Tumor response
was assessed using Response Evaluation Criteria in Solid
Tumors (RECIST, v1.0), with confirmation of responses
performed at least 4 weeks later.
Treatment and dose escalation
Ganetespib was administered over a 1-hour infusion,
once weekly for 3 weeks of a 4-week cycle. Intra-patient
dose escalation was allowed to dose levels shown to becentration vs. time curves. (A) Ganetespib (left) and 17-AAG, a
e ganetespib concentration vs. time curves for a 216 mg/m2 dose.
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lected based on a conservative estimate using the highest
non-severely toxic dose established in a once-weekly, 4-
week repeat dose study in cynomolgus monkeys. Dose
escalation followed a modified Fibonacci design resulting
in levels that escalated from 7 mg/m2 to 14, 23, 35, 49,
65, 86, 114, 150, 180, 216, and 259 mg/m2. Each cohort
consisted of 3 patients, with expansion to 6 patients if 1
of the 3 initial patients experienced a DLT, which was
defined as: Grade 4 thrombocytopenia (or Grade 3 with
hemorrhage); Grade 4 neutropenia lasting > 7 days (or
Grade 3 with fever); Grade 4 anemia; ≥ Grade 3 non-
hematologic toxicity (except alopecia); and ≥Grade 3
hypersensitivity despite premedication. Doses were esca-
lated after all patients in the preceding dose cohort had
completed Cycle 1. Dose reductions and delays of up to
14 days were allowed for recovery from toxicity. The
RP2D was defined as the dose of ganetespib below which
2 of 3 or 2 of 6 patients experienced a DLT. Once the
RP2D was determined, the respective cohort was ex-
panded up to 12 patients, to further define the safety
and pharmacokinetic profile.
Pharmacokinetic and pharmacodynamic analyses
Blood samples were taken for ganetespib plasma concentra-
tion determination on Days 1 and 15 of Cycle 1 pre-dose,
0.5, 1, 1.5, 2, 4, 6, 8 and 24 h after infusion initiation. Sam-
ples were also drawn pre-dose and at 1 h, on Day 8 of Cycle
1 and Days 1, 8 and 15 of subsequent cycles. Plasma was
separated and stored at a −70°C until analysis. Analyses
were performed by a validated HPLC-MS/MS method
under GLP conditions at Synta Pharmaceuticals Corp. Cali-
bration curve coefficients of determination (r2) ranged from
0.9897 to 0.9992. Back-calibrated calibration standards were
in good agreement with QC samples with bias ≤ ± 3%, and
calibration-curve r2 variation was ≤ ± 6.5% across a concen-
tration range of 0.100 through 100 ng/ml.
Pharmacokinetic parameters were computed non-
compartmentally using standard methods within a validated
installation of WinNonlin (v4.1, Pharsight Corporation, St.
Louis, MO). Parameters included the maximum concentra-
tion (Cmax), area under the plasma concentration versus
time curve (AUC), time of maximum concentration (Tmax),
and terminal elimination half-life (t1/2).
Pre-dose blood samples on Days 1, 8 and 15 of Cycle 1
and 2 were collected for assessment of HSP70 protein in
plasma by ELISA. Assays were performed using high sen-
sitivity HSP70 ELISA kits (Assay Design, Ann Arbor,
Michigan), with a sensitivity limit as low as 90 pg/ml,
according to manufacturers’ instructions. Results were
detected using a microplate ELISA reader at 450 nm with
a correction wavelength of 540 nm. Concentrations of
HSP70 were normalized to the total protein in each
plasma sample.No tumor biopsies were requested as part of the study
however archival tumor samples, collected prior to
ganetespib treatment, were available from a limited number
of patients. From those individuals with available tissue,
gene mutational analysis was carried out on DNA extracted
from archived tumor samples on the Sequenom
MassARRAY platform (53 genes; 649 mutations) according
to the manufacturer’s protocol.
Results
Patient characteristics
Fifty-three patients were enrolled in the study between
January 2008 and January 2010 and treated at doses escalat-
ing from 7 to 259 mg/m2. For purposes of data analyses,
dose levels were grouped to three cohorts: 7–114 mg/m2
(n = 25), 150–216 mg/m2 (n = 22), and 259 mg/m2 (n = 6);
and their baseline characteristics are shown in Table 1. All
53 patients were included in the analyses. However there
were 6 patients who retrospectively did not meet the eligi-
bility criteria, due to abnormal baseline hematological and
serum chemistry (n = 2, one patient enrolled at 7 mg/m2
and one enrolled at 216 mg/m2 dose levels), insufficient
cardiac function (n = 1, enrolled at 216 mg/m2 dose level),
or incomplete recovery from prior therapies (n = 3, two pa-
tients enrolled at 35 mg/m2 dose level, and one at 216 mg/
m2 dose level). The study population included patients with
a variety of solid tumors, with NSCLC being the most com-
mon (n = 10). The majority of patients were heavily pre-
treated, with 32 patients (60.3%) receiving at least 3 prior
systemic therapies.
Study treatment
All patients in the study received at least one dose of
ganetespib, with 5 patients (9.4%) receiving ≥ 8 cycles.
Three subjects (5.7%) dose-escalated without complication.
Dose modification was observed in 24 patients (45.3%):
missed dose (n = 16, 30.2%), dose reduction (n = 4, 7.5%), or
dose reduction and delay (n = 4, 7.5%), all mainly due to ad-
verse events. Three patients (5.7%), all in cohort 1,
discontinued ganetespib treatment due to drug-unrelated
adverse events: one patient with endometrial carcinoma
had hepatic failure that led to her death; one patient with
small cell lung cancer (SCLC) had spinal cord compression;
and one patient with esophageal cancer had biliary
obstruction.
Recommended phase II dose
None of the patients in the 7–114 mg/m2 cohort experi-
enced DLT, and therefore dose was escalated to next dose
levels. At the 150 mg/m2 dose level, one patient experi-
enced a DLT of asymptomatic, transient Grade 3 elevated
serum amylase. This dose level was expanded to 6 patients
with a 7th being added as one patient was deemed not
evaluable for dose escalation. No further DLT was observed
Table 1 Patients’ characteristics at baseline
Number (%) of patients
Ganetespib Ganetespib Ganetespib All
7-114 mg/m2 150-216 mg/m2 259 mg/m2 patients
n = 25 (%) n = 22 (%) n = 6 (%) n = 53 (%)
Age (years)
Median (range) 61 (39, 87) 62 (37, 80) 61 (47, 81) 61 (37, 87)
Sex, n (%)
Female 14 (56) 7 (31.8) 3 (50) 24 (45.3)
Male 11 (44) 15 (68.2) 3 (50) 29 (54.7)
Race, n (%)
White 24 (96) 19 (86.4) 6 (100) 49 (92.5)
Black 0 2 (9.1) 0 2 (3.8)
Other 1 (4) 1 (4.5) 0 2 (3.8)
ECOG PS, n (%)
0 10 (40) 5 (22.7) 2 (33.3) 17 (32.1)
1 13 (52) 17 (77.3) 4 (66.7) 34 (64.2)
2 2 (8) 0 0 2 (3.8)
Primary tumor site, n (%)
NSCLC 5 (20) 3 (13.6) 2 (33.3) 10 (18.9)
colorectal 2 (8) 6 (27.3) 0 8 (15.1)
Prostate 3 (12) 0 0 3 (5.7)
Esophageal 1 (4) 2 (9.1) 0 3 (5.7)
SCLC 1 (4) 1 (4.5) 0 2 (3.8)
Pancreas 1 (4) 1 (4.5) 0 2 (3.8)
Ovarian 2 (8) 0 0 2 (3.8)
Others 10 (40) 9 (40.9) 4 (66.7) 23 (43.3)
Tumor stage at study entry, n (%)
III 2 (8) 0 0 2 (3.8)
IV 23 (92) 22 (100) 6 (100) 51 (96.2)
Number of prior systemic therapies, n (%)
0 1 (4) 1 (4.5) 0 2 (3.8)
1 0 2 (9.1) 1 (16.7) 3 (5.7)
2-3 7 (28) 6 (27.3) 3 (50) 16 (30.2)
≥ 3 17 (68) 13 (59.1) 2 (33.3) 32 (60.4)
ECOG PS, Eastern Cooperative Oncology Group Performance Status.
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216 mg/m2 (n = 6) doses. The 216 mg/m2 cohort was ex-
panded to 6 patients due to an Investigator assessment of
Grade 3 QTc prolongation. A subsequent independent car-
diology review revealed technical factors that were deemed
the likely cause of the ECG findings. Possible confounding
factors included automated machine-read ECG QT inter-
vals that could not be duplicated upon expert cardiologist’s
over read; variation in lead placement; and the use of
Bazett’s correction formula, a method prone to over and
under correction. Based on this information, the Investiga-
tor updated his assessment and without QTc prolongation,the event was not deemed a DLT. At the 259 mg/m2 dose
level, two patients experienced DLTs of Grade 3 and 4 as-
thenia, and the dose level was expanded to 6 patients, with
one additional patient experiencing DLT of repeated Grade
3 diarrhea.
The 216 mg/m2 dose level was subsequently declared the
MTD and was further expanded with 6 additional patients.
One patient experienced Grade 3 fatigue, which would have
been considered dose-limiting in the dose-escalation phase.
The criteria for MTD of ≥ 2 out of 6 patients were not met,
and therefore did not affect the establishment of the phase
II dose. The dose was rounded to 200 mg/m2 as the
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28 day cycle.
Toxicity
All patients experienced at least one AE. The most
common toxicities reported during the study treat-
ment are listed in Table 2, and were diarrhea and fa-
tigue, with Grade 1 and 2 reported in 47 (88.7%) and
30 (56.6%) patients, respectively. The incidence of
diarrhea and fatigue increased with higher ganetespib
doses (7–114 mg/m2 dose levels: 80% and 48%;
150–216 mg/m2 dose levels: 95.5% and 59.1%; and
259 mg/m2 dose level: 100%, and 83.3%, respectively).Table 2 Adverse events of any grade reported in 10% or mor
Ganetespib
7-114 mg/m2 1
n = 25 (%)
Any event 25 (100)
Diarrhea 20 (60)
Fatigue 12 (48)
Abdominal pain 9 (36)
Nausea 7 (28)
Anemia 11 (44)
Decreased appetite 2 (8)
ALT elevated 5 (20)
Insomnia 2 (8)
Vomiting 4 (16)




Peripheral edema 3 (12)
Asthenia 2 (8)
Back pain 4 (16)




Weight decreased 1 (4)
Abdominal distension 3 (12)
ALT elevated 3 (12)
Dizziness 1 (4)
Dry mouth 2 (8)
Musculoskeletal chest pain 2 (8)
Extremity pain 4 (16)
Rash 4 (16)
*A patient may have had more than one event.In most patients (n = 40; 75.5%), the onset of diarrhea
occurred between days 1–7, and generally resolved
with anti-diarrheal treatment. Other frequent AEs
were mainly gastrointestinal, such as abdominal pain
(n = 20; 37.7%), nausea (n = 18; 34%) and vomiting
(n = 10; 18.9%), and were mild to moderate.
Elevated hepatic enzymes were infrequent and gener-
ally Grade 1 or 2. Ten (18.9%), 9 (17%), and 6 (11.3%)
patients had transient ALP, AST, and ALT elevation, re-
spectively. Four patients (7.5%) had Grade 2 or 3
hyberbilirubinemia; however, the events were not con-
sidered study drug-related, as most of these patients
presented with extensive hepatic metastases.e patients during study treatment, regardless of causality
Number (%) of patients*
Ganetespib Ganetespib All
50-216 mg/m2 259 mg/m2 patients
n = 22 (%) n = 6 (%) n = 53 (%)
22 (100) 6 (100) 53 (100)
21 (95.5) 6 (100) 47 (88.7)
13 (59.1) 5 (83.3) 30 (56.6)
10 (45.5) 1 (16.7) 20 (37.7)
7 (31.8) 4 (66.7) 18 (34)
5 (22.7) 0 16 (30.2)
8 (36.4) 1 (16.7) 11 (20.8)
5 (22.7) 0 10 (18.9)
6 (27.3) 2 (33.3) 10 (18.9)
3 (13.6) 3 (50) 10 (18.9)
4 (18.2) 0 9 (17)
3 (13.6) 1 (16.7) 9 (17)
4 (18.2) 1 (16.7) 9 (17)
6 (27.3) 1 (16.7) 9 (17)
5 (22.7) 1 (16.7) 9 (17)
4 (18.2) 2 (33.3) 8 (15.1)
2 (9.1) 2 (33.3) 8 (15.1)
3 (13.6) 3 (50) 8 (15.1)
3 (13.6) 3 (50) 7 (13.2)
4 (18.2) 1 (16.7) 7 (13.2)
2 (9.1) 0 7 (13.2)
5 (22.7) 1 (16.7) 7 (13.2)
3 (13.6) 0 6 (11.3)
3 (13.6) 0 6 (11.3)
3 (13.6) 2 (33.3) 6 (11.3)
3 (13.6) 1 (16.7) 6 (11.3)
4 (18.2) 0 6 (11.3)
1 (4.5) 1 (16.7) 6 (11.3)
1 (4.5) 1 (16.7) 6 (11.3)
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mild and transient. Three patients experienced Grade 1
or 2 blurred vision at doses of 35 mg/m2, 114 mg/m2
and 150 mg/m2. Grade 1 transient visual impairment
was reported in 2 patients (one each at doses of 216 and
259 mg/m2) each case considered to be possibly related
to study drug. Other changes were Grade 1 conjunctiv-
itis, eyelid edema, and night blindness, which were study
drug-unrelated.
One patient with a history of coronary artery disease
had Grade 1 atrio-ventricular block at 259 mg/m2, which
was possibly related to study drug. Three patients expe-
rienced QTc prolongation at higher dose levels on Cycle
1 Day 1 post-dose when QT = 438 ms, and QTc = 457
(QT with Bazett correction); however, a repeat ECG
performed later on the same day showed resolution of
the reported changes, with QT = 414 ms and QTc = 433.
QTc changes were reported in 48 patients (91%) that
were not symptomatic, did not lead to brady-
arrhythmias, and were not considered clinically mean-
ingful by an independent cardiologist who reviewed the
ECG data. No clinically significant changes were
detected in the vital sign measurements at any dose
level.
The most common hematological toxicities considered
by the investigators to be treatment-related were anemia
and neutropenia, occurring in 3 (5.7%) patients each.
A total of 36 patients (67.9%) experienced Grade 3 or
4 AE at some point in their participation, with fatigue
being the most commonly reported event (n = 6, 11.3%)
(Table 3).Table 3 Incidence of CTCAE Grade 3 and 4 adverse events (oc
Ganetespib
7-114 mg/m2 15
n = 25 (%)
Any event 17 (68)
Fatigue† 1 (4)
Asthenia† 1 (4)
Diarrhea † 1 (4)
Hypophosphatemia 2 (8)





Serum amylase elevated† 1 (4)
Hypokalemia† 0
Spinal cord compression 2 (8)
*A patient may have had more than one event.
†Considered by the investigator to be clinically significant.The number of patients with on-treatment SAEs is
shown in Table 4. None of the observed SAEs (n = 15,
28.3%) were considered treatment-related.
Three deaths were reported during the study; none
was deemed to be treatment-related. The causes of death
were hepatic failure, intestinal obstruction, and respira-
tory failure.
Clinical activity
Forty-two patients were evaluable for clinical activity,
and 11 patients discontinued treatment before first dis-
ease assessment (Table 5). One patient with metastatic
colorectal cancer had a PR, and 23 patients (43.4%) had
SD (range 46–563 days). No tumor tissue was available
from the patient achieving the PR, hence the mutational
status of this tumor was unknown. Disease control rate
(PR and SD ≥ 16 weeks) was 24.5%.
A total of 10 patients presented with NSCLC; of these
6 patients (60%) had SD for at least 8 weeks. One patient
receiving ganetespib at 150 mg/m2 had a maximum re-
duction in target lesions of 26.5% and remained on study
for 13 months. Molecular profiling revealed a BRAF
G469A mutation. For this individual, circulating plasma
HSP70 levels increased following ganetespib dosing and
remained elevated during both treatment cycles, peaking
at 750 and 730 ng/g in Cycles 1 and 2, respectively.
Another patient with metastatic GIST receiving
ganetespib at 216 mg/m2 attained durable disease stabi-
ization with a maximum reduction in target lesions of
18%. Mutational analysis showed PDGFRAD842V exon
18 mutation.curring in ≥ 2 patients), regardless of causality
Number (%) of patients*
Ganetespib Ganetespib All
0-216 mg/m2 259 mg/m2 patients
n = 22 (%) n = 6 (%) n = 53 (%)
14 (63.6) 5 (83.3) 36 (67.9)
4 (18.2) 1 (16.7) 6 (11.3)
1 (4.5) 2 (33.3) 4 (7.5)
2 (9.1) 1 (16.7) 4 (7.5)
2 (9.1) 0 4 (7.5)
1 (4.5) 0 3 (5.7)
1 (4.5) 1 (16.7) 3 (5.7)
2 (9.1) 0 3 (5.7)
0 0 3 (5.7)
0 1 (16.7) 2 (3.8)
1 (4.5) 0 2 (3.8)
2 (9.1) 0 2 (3.8)
0 0 2 (3.8)
Table 4 Number (%) of patients with serious adverse events (that affected ≥ 2 patients)
Number (%) of patients*
Ganetespib Ganetespib Ganetespib All
7-114 mg/m2 150-216 mg/m2 259 mg/m2 patients
n = 25 (%) n = 22 (%) n = 6 (%) n = 53 (%)
Any event 6 (24) 6 (27.3) 3 (50) 15 (28.3)
Abdominal pain 0 1 (4.5) 1 (16.7) 2 (3.8)
Asthenia 0 1 (4.5) 1 (16.7) 2 (3.8)
Dehydration 0 1 (4.5) 1 (16.7) 2 (3.8)
Pneumonia 0 1 (4.5) 1 (16.7) 2 (3.8)
*A patient may have had more than one event.
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was treated with ganetespib (259 mg/m2) and achieved
disease stabilization over 20 months. However, gene mu-
tational analysis was inconclusive.
Pharmacokinetics
Ganetespib concentration rose rapidly during infusion
and declined rapidly upon termination. The concentra-
tion of ganetespib declined to approximately 10% of
Cmax within 1 h of infusion termination and 1% of Cmax
within 8 to 10 h (Figure 1B). Day 1 and 15 concentration
profiles were similar and there was no apparent drug ac-
cumulation for these once-weekly doses.
The mean ± SD terminal t1/2 was approximately 7.54 ±
2.64 h and plasma drug clearance was 52.59 ±17.80 L/h or
28.55 ± 9.33 L/h/m2. Mean Tmax was at 0.79 h. During in-
fusion samples were drawn at 0.5 and 1 h. Tmax occurrence
at the time of the 0.5 h sample in 39% of drug administra-
tions is consistent with a rapid alpha phase and suggests
that the drug achieves near maximal concentrations within
the first 30 min of infusion initiation (Figure 1B). Mean
steady state volume of distribution (Vss) was 196 ± 172 L or
107 ± 98 L/m2. Clearance and volume of distribution wereTable 5 Investigator-evaluated assessment of best overall res
Ganetespib
7-114 mg/m2
n = 25 (%)
Best responsea, n (%)
Complete response 0
Partial response 1 (4)
Stable disease 10 (40)
Progressive disease 10 (40)
Non-evaluableb 4 (16)
Disease control rate (≥ 8 weeks)c 11 (44)
Disease control rate (≥ 16 weeks)d 5 (20)
aInitial assessment at 8 weeks from treatment start with confirmation assessment a
bReasons for non-evaluable patients: investigator decision (2), symptom deterioratio
cdisease control rate: Complete and partial responses, and stable disease ≥ 8 weeks
ddisease control rate: Complete and partial responses, and stable disease ≥ 16 weekapproximately constant across doses. AUC increased in
proportion to dose for each of Days 1 and 15 (Figure 2A).
The relationship of AUC to dose for the two days was es-
sentially identical, as shown in the individual-day regres-
sion lines. As such, the data from Days 1 and 15 were
combined to provide a single descriptor of AUC versus
dose. The coefficient of determination (r2) was 0.7547.
Cmax also increased in relative proportion to dose, with
Day 1 and 15 being similar (Figure 2B). Linear regression of
the combined data from Days 1 and 15 gave an r2 value of
0.7367. Indeed, ganetespib Cmax was an excellent predictor
of AUC, with a coefficient of determination of 0.9270. Re-
gression analysis also suggested that there were no statisti-
cally significant associations between Cmax or AUC and
diarrhea (P = 0.17).
Pharmacodynamics
For a majority of the patients evaluated, baseline Hsp70
plasma protein levels were low, but were significantly ele-
vated on Days 8 and 15 (immediately prior to the second
and third administration of ganetespib, respectively). This
increase in response to ganetespib administration is indica-
tive of ganetespib bioactivity in patients and, importantly,ponse
Ganetespib Ganetespib Overall
150-216 mg/m2 259 mg/m2 response
n = 22 (%) n = 6 (%) n = 53 (%)
0 0 0
0 0 1 (1.9)
11 (50) 2 (33.3) 23 (43.4)
5 (22.7) 3 (50) 18 (34)
6 (27.3) 1 (16.7) 11 (20.8)
11 (50) 2 (33.3) 24 (45.3)
6 (27.3) 2 (33.3) 13 (24.5)
t least 4 weeks later.
n (8) and withdrawal of informed consent (1).
.
s.
Figure 2 Pharmacokinetic linearity plots. (A) AUC vs. Dose and (B) Cmax vs. Dose. Diamonds represent Day 1, triangles represent Day 15. Solid
line represents linear regression of Day 1 and Day 15 data combined. Dotted line is Day 1 only. Dashed and dotted line is Day 15 only. For Days
1 and 15 combined, coefficients of determination for AUC and Cmax were 0.7547 and 0.7637, respectively.
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the second treatment cycle. Elevated HSP70 protein plasma
levels persisted for at least a week following drug exposure.
Additionally, the higher mean maximum increase of HSP70
observed in Cycle 1 suggested that Hsp70 induction satu-
rates at dose levels above 180 mg/m2, further supporting
the selection of the 200 mg/m2 dose for Phase 2 (Figure 3).
There was no statistically significant association between
HSP70 induction and DCR at 8 weeks (P < 0.79), or with
diarrhea incidence (P < 0.81).Discussion
We report here the first-in-human phase I study of
ganetespib administered once weekly for 3 weeks of a 4-
week cycle. This study demonstrated dose-proportional
pharmacokinetics and tolerability at doses ranging from
7 mg/m2 to 216 mg/m2 in patients with advanced solid
malignancies. There were no DLTs in the 216 mg/m2 dose
escalation cohort, and therefore, this dose was rounded to
200 mg/m2 and selected as the RP2D of ganetespib. After
this phase I study, ganetespib 200 mg/m2 has been studiedFigure 3 Plasma HSP70 protein concentrations on days 1, 8
and 15 of Cycle 1 for 7–114 mg/m2 and 150–259 mg/m2 dose
groups.in several phase II studies as a single agent, and has shown
to be well tolerated.
The most common toxicities were diarrhea and fatigue.
Although there was no correlation with AUC or Cmax,
diarrhea incidence appeared to increase with increasing
doses of ganetespib, and it may serve as a PD biomarker
for ganetespib. Diarrhea has also been observed with other
Hsp90 inhibitors [18-21], suggesting that it may be a
mechanism-based toxicity rather than an off-target effect.
EGFR, a known client protein to Hsp90, is recognized to
play a key role in intestinal epithelial integrity and restitu-
tion [22-24]. Consequently, proactive diarrhea manage-
ment is incorporated in recent ganetespib clinical trials.
Two patients in the current study experienced treatment-
related visual impairment, which were mild and transient.
Hsp90 plays a key role in the folding of key signaling mole-
cules required to maintain retinal function. Visual disor-
ders, including blurred vision, flashes, delayed light/dark
accommodation and photophobia, have been reported with
other Hsp90 inhibitors, suggesting retinal injury [21,25-27].
It was recently postulated that high retinal exposure and
the slow elimination rate of several Hsp90 inhibitors with
hydrophilic properties led to induction of apoptosis in the
retinal outer nuclear layer [28]. Over 400 patients have been
treated to date with ganetespib in other studies. The inci-
dence of treatment related visual changes is <3% (unpub-
lished observation) suggesting that the physicochemical
properties of ganetespib molecular structure may provide a
favorable safety profile [12]. No formal ophthalmologic
examination was required in this study.
Clinical activity of ganetespib was demonstrated in heav-
ily pre-treated patients with metastatic cancers. Disease
stabilization was generally associated with doses higher
than 80 mg/m2. However, due to the limited response
data, it was not possible to characterize the relationship
between exposure to ganetespib and clinical activity. How-
ever clinical effect may be linked to the biological profile
of the tumor since two patients, who presented with
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http://www.biomedcentral.com/1471-2407/13/152NSCLC and GIST and achieved SD, had tumors harboring
BRAF G469A and PDGFRAD842V exon 18 mutations, re-
spectively. Interestingly, activated BRAF [29] and mutated
PDGFRA [30] are known client proteins requiring Hsp90,
and these oncogenes can be effectively degraded by Hsp90
inhibitors [30-32]. Ongoing clinical trials are currently fo-
cusing on identifying the predictors of response to
ganetespib treatment, based on molecular characterization
of tumor tissues.
The up-regulation of HSP70 is used as a marker of
Hsp90 inhibition [21,33-36]. We have evaluated the
levels of serum HSP70 as a surrogate of intracellular
HSP70 induction [11]. Although ganetespib induced ele-
vations in circulating HSP70, serum levels were variable
and did not appear to correlate with the ganetespib dose.
Thus, HSP70 up-regulation as a pharmacodynamic read-
out appears to be indicative of biological activity of the
drug, but does not predict for tumor response. Similar
observations have been reported in clinical trials of other
Hsp90 inhibitors [18,37] that have typically investigated
HSP70 up-regulation in PBMCs as part of their pharma-
codynamic analyses. PBMCs were not evaluated in this
study, since HSP70 expression in these cells had previ-
ously showed limited utility as a surrogate tissue for
ganetespib activity in a separate trial (I. El-Hariry, un-
published data).
Ganetespib demonstrated linear PK with Cmax and
AUC increasing in proportion to dose. Cmax and AUC
were highly correlated indicating that Cmax is a good
predictor of overall exposure, presuming distribution
and elimination processes are unaltered. Drug elimin-
ation is rapid relative to the dosing frequency. Overall
variability in exposure is small to moderate, as repre-
sented by a coefficient of variation of 33.8% for clearance
(the reciprocal of dose-normalized AUC).
Conclusions
In conclusion, once weekly dosing of ganetespib is well
tolerated. The RP2D is 200 mg/m2, and is associated with
an acceptable safety profile. Based on these findings, mul-
tiple phase II studies have been initiated. Ganetespib is
currently being investigated in a global randomized phase
II/III study in combination with docetaxel in 2nd line
NSCLC patients.Abbreviations
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